Tag: Timothy Miller

Grant will fund development of vaccines to prevent dementia

Alzheimer’s disease and frontotemporal dementia are devastating disorders that emerge following the buildup of misfolded proteins in the brain. The newest generation of Alzheimer’s therapeutics targets accumulations of the protein amyloid beta with engineered antibodies, but the results have been underwhelming, with some adverse effects, not to mention using engineered antibodies can be prohibitively expensive. […]

Drug for rare form of ALS, based in part on WashU research, approved by FDA

A new drug has been approved by the Food and Drug Administration (FDA) for a rare, inherited form of amyotrophic lateral sclerosis (ALS), a paralyzing neurological disease. Known as tofersen, the drug has been shown to slow progression of the deadly disease. International clinical trials of tofersen, developed by the global biotechnology company Biogen Inc., […]

Future Thoughts and Reason for Excitement in ALS: Timothy Miller, MD, PhD

“These trials don’t go without huge input and commitment from the participants and of course, their caregivers, and the clinical trial sites. I have the privilege of speaking to you about the trial as the lead author of this paper, but this is a team effort and includes a large group of people from multiple […]